Literature DB >> 17304470

Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz.

Polina German, Bryan Greenhouse, Carrie Coates, Grant Dorsey, Philip J Rosenthal, Edwin Charlebois, Niklas Lindegardh, Diane Havlir, Francesca T Aweeka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17304470     DOI： 10.1086/511882

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  27 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.

Authors:  Kimberly K Scarsi; Fatai A Fehintola; Qing Ma; Francesca T Aweeka; Kristin M Darin; Gene D Morse; Ibrahim Temitope Akinola; Waheed A Adedeji; Niklas Lindegardh; Joel Tarning; Oladosu Ojengbede; Isaac F Adewole; Babafemi Taiwo; Robert L Murphy; Olusegun O Akinyinka; Sunil Parikh
Journal:  J Antimicrob Chemother       Date:  2014-01-19       Impact factor: 5.790

3.  Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings.

Authors:  Jose R Castillo-Mancilla; Thomas B Campbell
Journal:  J Comp Eff Res       Date:  2012-03       Impact factor: 1.744

4.  The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.

Authors:  Moses R Kamya; Pauline Byakika-Kibwika; Anne F Gasasira; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan
Journal:  Future Virol       Date:  2012       Impact factor: 1.831

5.  Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.

Authors:  Anyirékun Fabrice Somé; Yves Y Séré; Christian Dokomajilar; Issaka Zongo; Noël Rouamba; Bryan Greenhouse; Jean-Bosco Ouédraogo; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 6.  Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa.

Authors:  Fatai A Fehintola; Olusegun O Akinyinka; Isaac F Adewole; Chiedza C Maponga; Qing Ma; Gene D Morse
Journal:  Curr Drug Metab       Date:  2011-01       Impact factor: 3.731

7.  Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Authors:  Catia Marzolini; Rajith Rajoli; Manuel Battegay; Luigia Elzi; David Back; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

8.  In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19.

Authors:  Cong Xu; Zeruesenay Desta
Journal:  Drug Metab Pharmacokinet       Date:  2013-02-05       Impact factor: 3.614

Review 9.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.

Authors:  George O Adjei; Kim Kristensen; Bamenla Q Goka; Lotte C G Hoegberg; Michael Alifrangis; Onike P Rodrigues; Jorgen A L Kurtzhals
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.